528 related articles for article (PubMed ID: 32114686)
1. Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists.
Sueta D; Yamamoto E; Tsujita K
Curr Hypertens Rep; 2020 Feb; 22(3):21. PubMed ID: 32114686
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.
Tezuka Y; Ito S
Curr Hypertens Rep; 2022 Jul; 24(7):215-224. PubMed ID: 35488944
[TBL] [Abstract][Full Text] [Related]
4. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
5. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
[TBL] [Abstract][Full Text] [Related]
6. [Multidisciplinary expert consensus for clinical application of mineralocorticoid receptor antagonists in China].
;
Zhonghua Nei Ke Za Zhi; 2022 Sep; 61(9):981-999. PubMed ID: 36008291
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
Young MJ; Kanki M; Karthigan N; Konstandopoulos P
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
Dojki FK; Bakris G
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Colussi G; Catena C; Sechi LA
J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
[TBL] [Abstract][Full Text] [Related]
12. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
13. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
Kolkhof P; Bärfacker L
J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
[TBL] [Abstract][Full Text] [Related]
14. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
Grune J; Beyhoff N; Smeir E; Chudek R; Blumrich A; Ban Z; Brix S; Betz IR; Schupp M; Foryst-Ludwig A; Klopfleisch R; Stawowy P; Houtman R; Kolkhof P; Kintscher U
Hypertension; 2018 Apr; 71(4):599-608. PubMed ID: 29437893
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics.
Barrera-Chimal J; Kolkhof P; Lima-Posada I; Joachim A; Rossignol P; Jaisser F
Expert Opin Investig Drugs; 2021 Nov; 30(11):1141-1157. PubMed ID: 34758679
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
Watson K; Kukin A; Wasik AK; Shulenberger CE
J Cardiovasc Pharmacol; 2021 Jun; 77(6):685-698. PubMed ID: 34057158
[TBL] [Abstract][Full Text] [Related]
18. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
20. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
